BeiGene

BeiGene is a global, science-driven oncology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. Since its founding in 2010, it has emerged as a leader in the field of biotechnology, primarily concentrating on oncology and hematology. The company is dedicated to enhancing cancer treatment by advancing a diverse portfolio of high-quality therapeutics that address numerous types of cancer, thereby reducing the financial barriers that patients often face.

BeiGene aims to revolutionize the oncology landscape through significant investments in research and development, fostering partnerships with leading healthcare professionals and organizations globally. One of its key philosophies is that cancer has no borders, and the company is committed to breaking barriers to access cancer treatment around the world. With more than 10,000 colleagues across five continents, BeiGene is working tirelessly to make its innovations accessible to all patients, regardless of their geographical location. Their success is reflected in various initiatives, such as collaborations with international health authorities and extensive clinical trial programs aimed at delivering new treatment options rapidly and effectively.